TARS

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Irvine, California. The company went public in October 2020 and has since established itself as a pioneer in developing treatments for parasitic infestations affecting the eye. Tarsus achieved a significant milestone in 2023 with the FDA approval and commercial launch of XDEMVY, the first and only approved treatment for Demodex blepharitis, a common eye condition caused by microscopic mites. The company has transitioned from a pure research and development stage to a commercial-stage pharmaceutical company, generating substantial revenue from its flagship product while continuing to advance its pipeline of lotilaner-based therapeutics.